The company's U.S. headquarters are in the ON3 complex in Nutley and Clifton. Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records ...

STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi.

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

As of 12:17:47 PM EDT. Market Open. Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. Weeks after Eisai quietly made its choice, its liquid biopsy partner has revealed Bliss ...

Lecanemab, the first medication designed to remove amyloid beta, a protein believed to cause Alzheimer’s, was developed by Japan’s Eisai Co. and its U.S. partner, Biogen Inc. “We believe ...

TOKYO -- Japanese drugmaker Eisai's share price is hovering around a 10-year low of 4,300 yen, weighed down by poor U.S. sales of its much-touted Alzheimer's treatment Leqembi and the company's ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to decline the approval of humanized anti-soluble ...

Feb 28 (Reuters) - The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Alzheimer's drug ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has reaffirmed its positive opinion by consensus for ...

Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records show, as the pharmaceutical company shaves off 7% of its U.S. workforce.